Psychosomatic disease
Methodology & AI Transparency ⓘ
Psychosomatic disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code F54 in Depression & Mood, Psychosomatic disease requires validated longitudinal mood in Psychosomatic disease (F54: rating scales (PHQ-9) so specialists can calibrate treatment intensity against PHQ-9 Symptom Severity in Psychosomatic disease (F54: Score) benchmarks.
- 2 Real-world patient consensus: Clinical coding for Psychosomatic disease uses ICD-10 F54 across Depression & Mood specialty care.
- 3 Typical cash cost range: Clinicians assessing Psychosomatic disease focus on circadian phase instability [Psychosomatic disease F54] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Psychosomatic disease monitoring tracks PHQ-9 Symptom Severity in Psychosomatic disease (F54: Score) toward < 4 (clinical remission) (F54).
Ask our AI Specialists anything about Psychosomatic disease
What Is Psychosomatic disease?
Cataloged under federal diagnostic code F54 in Depression & Mood, Psychosomatic disease requires validated longitudinal mood in Psychosomatic disease (F54: rating scales (PHQ-9) so specialists can calibrate treatment intensity against PHQ-9 Symptom Severity in Psychosomatic disease (F54: Score) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
In Psychosomatic disease (F54), physiological disruption stems from circadian phase instability [Psychosomatic disease F54], informing Depression, Bipolar & Mood Disorders protocols that track TSH & Free in Psychosomatic disease (F54: T4 Rule-Out) (TSH 0.8 – 2.5 mIU/L (F54)).
Common Symptoms & Clinical Signs
- • Presentation of Psychosomatic disease (F54): slowed concentration, indecisiveness, in Psychosomatic disease (F54: and physical heaviness)
- • Secondary Psychosomatic disease clinical sign: loss of interest in Psychosomatic disease (F54: or pleasure in)
- • Symptom flares in Psychosomatic disease correlating with PHQ-9 Symptom Severity in Psychosomatic disease (F54: Score) deviation outside < 4 (clinical remission) (F54)
- • Functional depression & mood impact requiring validated longitudinal mood in Psychosomatic disease (F54: rating scales (PHQ-9) evaluation (F54)
Psychosomatic disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F54 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Psychosomatic disease (F54: Score) | < 4 (clinical remission) (F54) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Psychosomatic disease (F54: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F54) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Psychosomatic disease (F54: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F54) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Psychosomatic disease
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Carbamazepine ER Carbatrol • RxCUI 199378 | Mood Stabilizer | 84% | $0.1989 | $ 7.25 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Psychosomatic disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy, tolerability, and acceptability of bupropion for: What a 1,117-Participant Study Found According to the limited data obtained from three RCTs, bupropion XL is as effective and tolerable as venlafaxine XR for adult patients with MDD. Drug design, development and therapy • 2013-01-15 • Meta-Analysis | N = 1,117 | 94/100 | PMID 24101861 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of AXS-05 (Dextromethorphan-Bupropion) in depression: A Randomized In patients with major depression, dextromethorphan-bupropion (AXS-05) significantly improved depressive symptoms compared with bupropion and was generally well tolerated. The American journal of psychiatry • 2022-07-15 • Randomized Controlled Trial | N = 43 | 88/100 | PMID 35582785 ↗ |
| Can This Approach Help? Inside the Latest Research on Sexual Function With Adjunctive Lumateperone in Patients With Conclusions: Adjunctive lumateperone 42 mg did not worsen sexual functioning and was not associated with treatment-related sexual dysfunction in patients with MDD with inadequate response to ADT. The Journal of clinical psychiatry • 2026-09-02 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42690086 ↗ |
| Can This Approach Help? Inside the Latest Research on Antipsychotic Medication on Brain Structure in Patients With depression and Eighty-eight participants (age range, 18-85 years) completed a baseline scan; 75 completed a follow-up scan, of which 72 (32 men and 40 women) were useable for final analyses. JAMA psychiatry • 2020-07-01 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 32101271 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Current treatment options for treatment-resistant depression have considerable limitations in terms of efficacy and patient acceptability. The American journal of psychiatry • 2019-06-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 31109201 ↗ |
Psychosomatic disease Patient Community & “People Like Me” Threads
Filter Psychosomatic disease community threads and patient logs by age, biological sex, dosage, and treatment duration.